337 related articles for article (PubMed ID: 29432315)
1. Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review.
Liesse K; Harris J; Chan M; Schmidt ML; Chiu B
J Pediatr Hematol Oncol; 2018 Aug; 40(6):417-425. PubMed ID: 29432315
[TBL] [Abstract][Full Text] [Related]
2. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
[TBL] [Abstract][Full Text] [Related]
4. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
Wu V
J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
[TBL] [Abstract][Full Text] [Related]
5. Minimizing cardiac toxicity in children with acute myeloid leukemia.
Narayan HK; Getz KD; Leger KJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients.
Kang M; Kim KI; Song YC; Shin WG; Oh JM
J Chemother; 2012 Oct; 24(5):292-6. PubMed ID: 23182049
[TBL] [Abstract][Full Text] [Related]
7. Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients.
Kim H; Kang HJ; Park KD; Koh KN; Im HJ; Seo JJ; Lee JW; Chung NG; Cho B; Kim HK; Lee JM; Hah JO; Lee JA; Lee YH; Park SK; Baek HJ; Kook H; Kim JY; Kim HS; Kim HM; Chueh HW; Park M; Yoon HS; Lee MJ; Choi HS; Ahn HS; Kawano Y; Park JW; Hahn S; Shin HY
Cancer Res Treat; 2019 Jan; 51(1):357-367. PubMed ID: 29764117
[TBL] [Abstract][Full Text] [Related]
8. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
10. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
[TBL] [Abstract][Full Text] [Related]
11. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular disease in survivors of childhood cancer.
Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
[TBL] [Abstract][Full Text] [Related]
13. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
Shaikh F; Dupuis LL; Alexander S; Gupta A; Mertens L; Nathan PC
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598513
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Choi HS; Park ES; Kang HJ; Shin HY; Noh CI; Yun YS; Ahn HS; Choi JY
J Korean Med Sci; 2010 Sep; 25(9):1336-42. PubMed ID: 20808678
[TBL] [Abstract][Full Text] [Related]
16. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
Cvetković RS; Scott LJ
Drugs; 2005; 65(7):1005-24. PubMed ID: 15892593
[TBL] [Abstract][Full Text] [Related]
17. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
de Baat EC; van Dalen EC; Mulder RL; Hudson MM; Ehrhardt MJ; Engels FK; Feijen EAM; Grotenhuis HB; Leerink JM; Kapusta L; Kaspers GJL; Merkx R; Mertens L; Skinner R; Tissing WJE; de Vathaire F; Nathan PC; Kremer LCM; Mavinkurve-Groothuis AMC; Armenian S
Lancet Child Adolesc Health; 2022 Dec; 6(12):885-894. PubMed ID: 36174614
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
19. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
20. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
